Radiopharm Theranostics (ASX:RAD) has announced an oral presentation at EANM 2023 from Investigator-Initiated Research2 (IIR) conducted by the Fortis Memorial Research Institute.
The presentation is for clinical data of 68Ga-Trivehexin (RAD 301) for the imaging of Pancreatic Ductal Adenocarcinoma (PDAC) and Head and Neck Squamous Cell Carcinomas (H&N SCCs).
The current imaging standards of care for the detection of PDAC, F-fluoro-deoxy-glucose positron emission tomography (FDG PET), and Magnetic Resonance Imaging (MRI) have significant limitations.
The company said the pilot study demonstrated that 68Ga-Trivehexin PET/CT has higher accuracy than F18-FDG PET/CT in the detection of primary and metastatic lesions in PDAC and H&N SCCs.
It said the results were presented during an oral session at the 2023 annual EANM congress in Vienna, highlighting the strong potential for 68Ga-Trivehexin as a promising molecular imaging agent for tumours expressing αvβ6 integrin.
In May 2023, the FDA granted Radiopharm with an Orphan Drug Designation (ODD) for Trivehexin (RAD 301) in pancreatic cancer.
“Pancreatic cancer has one of the highest levels of unmet meet, posing a challenge for healthcare providers imaging and treating PDAC patients,” said Riccardo Canevari, CEO and managing director of Radiopharm Theranostics.
“The findings from the Fortis Memorial Research Institute not only serve to strengthen the existing data for Trivehexin radiopharmaceuticals for imaging and treating PDAC, but also show strong potential for follow-on indications that include H&N SCCs, potentially providing all patients with cancers expressing αvβ6-integrin alternative and much-needed imaging and treatment options.”
Radiopharm has signed an exclusive licensing agreement with TRIMT GmbH for the development and commercialisation of RAD 301 in the US, Australia, China, Hong Kong, and Japan.